Cargando…
Single arm NCRI phase II study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter’s syndrome
BACKGROUND: Transformation of B-cell chronic lymphocytic leukaemia (B-CLL) to diffuse large B cell lymphoma (DLBCL) (Richter’s syndrome (RS)) is a rare (2-15% of patients) but catastrophic complication of B-CLL. Dose-intense chemotherapy regimens investigated in small single institution trials, but...
Autores principales: | Eyre, Toby A, Clifford, Ruth, Roberts, Corran, Boyle, Lucy, Francis, Anne, Schuh, Anna, Dutton, Susan J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329650/ https://www.ncbi.nlm.nih.gov/pubmed/25775024 http://dx.doi.org/10.1186/s12885-015-1048-9 |
Ejemplares similares
-
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial
por: Pettitt, Andrew R., et al.
Publicado: (2020) -
The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease
por: Appleby, Niamh, et al.
Publicado: (2019) -
Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B‐Cell Lymphoma Who Are Poor Candidates for R‐CHOP Chemotherapy
por: Flinn, Ian W., et al.
Publicado: (2019) -
Cellular Therapy in High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter Syndrome
por: Barbanti, Maria Chiara, et al.
Publicado: (2022) -
Cancer Informatics in the U.K.: The NCRI Informatics Initiative
por: Reddington, Fiona, et al.
Publicado: (2007)